AGA is seeking your public comments on our newest quality measure, developed based on the clinical recommendations in the AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia (GIM).
One of the strongest recommendations from this guideline is to test all GIM patients for H. pylori followed by eradication over no testing and eradication. With rising H. pylori antibiotic resistance and declining eradication rates, confirmation of eradication is necessary to ensure that H. pylori treatment is effective. Multiple studies report post-treatment H. pylori testing rates are currently less than 60%. This quality gap provides an opportunity to improve the care of patients with GIM and H. pylori infection.
Our quality measure, now available for public review, details how to best track and report on your performance following this clinical recommendation.
Review the quality measure below and submit your feedback by Dec. 4.
Measure specification
Share feedback
About quality and performance measures
AGA has been instrumental in assuring that GI has a place at the table concerning quality, influencing the national agenda through developing, specifying, maintaining, testing and implementing quality measures, and through membership and participation in the Physician Consortium for Performance Improvement, the Centers for Medicare and Medicaid Services (CMS) Quality Payment Program and other national organizations.
The AGA Institute Quality Committee (QC) provides clinical and methodological expertise and oversight for the development, specification, maintenance and testing of AGA’s performance measures.
AGA follows a process for prioritizing and developing measures from AGA guidelines. Public comment periods are held to receive feedback from gastroenterologists and others interested in new AGA measures.
Learn more at https://gastro.org/quality
